UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~June 16~~January 12, ~~2009~~2010

Date of Report – (Date of earliest event reported)

CHEM RX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-51518	20-2938469
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

750 Park Place

Long Beach, New York 11561

(Address of principal executive office, including zip code)

(516) 889-8770

(Registrant’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~o ~~8.01~~Soliciting –material ~~Other~~pursuant ~~Event~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Ono ~~June~~Pre-commencement ~~16,~~communications ~~2009,~~pursuant ~~Chem~~to RxRule ~~Corporation~~ 14d-2(~~the “Company”~~b) ~~issued a press release announcing that it has signed extensions of the forbearance agreements with the lenders~~ under ~~its two primary credit facilities. A copy of~~ the ~~press~~Exchange ~~release~~Act is(17 ~~attached~~CFR ~~as Exhibit 99~~240.~~1 to this current report on Form 8~~14d-~~K and is incorporated herein by reference.~~ 2(b))

~~The~~o ~~information in this Form 8~~Pre-K,commencement ~~including~~communications ~~the~~pursuant ~~Exhibit~~to ~~attached~~Rule ~~hereto,~~13e-4(c) ~~shall~~under ~~not be deemed “filed” for purposes of Section 18 of~~ the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR ~~nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing~~240.13e-4(c))

Item 9 5.~~01:~~02 ~~Financial~~– ~~Statements~~Departure ~~and~~of ~~Exhibits~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)	Exhibits.
	Exhibits	Descriptions
	99.1	Press release dated June 16, 2009.

(b) On January 12, 2010, J. Jay Lobell and David J. Kellman resigned from the board of directors of Chem Rx Corporation (“Chem Rx”).

2(d) On January 15, 2010, Gary M. Jacobs and Evan Selzer were appointed directors of Chem Rx.

~~SIGNATURES~~Gary M. Jacobs is the Chief Financial Officer of Chem Rx. He became Chief Financial Officer of Chem Rx on June 12, 2008. From May 2005 to June 2008, Mr. Jacobs was the Chief Financial Officer and Chief Operating Officer of Gold Force International, Ltd., a supplier of gold, silver and pearl jewelry to U.S. retail chains, and Karat Platinum LLC, a developer of an alternative to platinum. From July 2003 to April 2005, Mr. Jacobs served as President of The Innovative Companies, LLC, a supplier of natural stone. From October 2001 to February 2003, Mr. Jacobs served as Executive Vice President of Operations and Corporate Secretary of The Hain Celestial Group, Inc., a food and personal care products company. Mr. Jacobs also served as Executive Vice President of Finance, Chief Financial Officer and Treasurer of The Hain Celestial Group, Inc. from September 1998 to October 2001. Prior to that, Mr. Jacobs was the Chief Financial Officer of Graham Field Health Products, Inc., a manufacturing and distribution company. Mr. Jacobs was employed for 13 years as a member of the audit staff of Ernst & Young LLP, where he attained the position of senior manager. He is a certified public accountant and holds a Bachelor’s of Business Administration in Accounting from Adelphi University.

~~Pursuant~~Evan toSelzer ~~the~~is ~~requirements~~currently an Executive Vice President of ~~the~~Chem ~~Securities~~Rx. Mr. ~~Exchange~~Selzer ~~Act~~has been employed by Chem Rx since March 1989 in various senior management positions including Director of ~~1934,~~Purchasing ~~the~~and ~~registrant~~Vice ~~has~~President. His ~~duly~~breadth ~~caused~~of ~~this~~experience includes ~~report~~all tooperations beof ~~signed~~Chem onRx’s ~~its~~pharmacy, ~~behalf~~stock, bydelivery ~~the~~and ~~undersigned~~purchasing departments. Mr. ~~thereunto~~Selzer’s ~~duly~~current ~~authorized~~responsibilities include product purchasing, new technology and general operations.

	CHEM RX CORPORATION
Dated: June 16, 2009	By:	/s/ Steven Silva
	Name:	Steven Silva
	Title:	President and Chief Operating Officer

SIGNATURES

3Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~EXHIBIT~~CHEM ~~INDEX~~RX CORPORATION

	Exhibits		Descriptions
Dated: January 19, 2010		By:	/s/ Steven Silva
	99.1		Press release dated June 16, 2009.
			Name: Steven Silva
			Title: President and Chief Operating Officer

Filing Compare · CHEM RX CORP